Sarissa Capital Management and Aegerion Pharmaceuticals, Inc. (AEGR) Amend Nomination Agreement

Page 3 of 3

Page 3 of 3 – SEC Filing

CUSIP No.  00767E102
Page 3 of  3 Pages
SCHEDULE 13D
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated:  March 22, 2016
SARISSA CAPITAL MANAGEMENT LP
By:
/s/ Mark DiPaolo                                       
Name: Mark DiPaolo
Title: General Counsel
SARISSA CAPITAL DOMESTIC FUND LP
By: Sarissa Capital Fund GP LP, its general partner
By:
/s/ Mark DiPaolo                                       
Name: Mark DiPaolo
Title: Authorized Person
SARISSA CAPITAL OFFSHORE MASTER FUND LP
By: Sarissa Capital Offshore Fund GP LLC, its general partner
By:
/s/ Mark DiPaolo                                       
Name: Mark DiPaolo
Title: Authorized Person
/s/Alexander J. Denner                                               
Alexander J. Denner

Follow Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Page 3 of 3